Skip to main content
idi
Toggle navigation
0
You have 0 notifications
Site Visitor
Site Visitor
New To Inknowvation.com?
Register now to get an access to proprietary SBIR-STTR databases!
Registration is fast and free - start your access to business-actionable information today!
Login
Site Register
SBIR-STTR Award
You are here:
Home
Search Databases
Search SBIR-STTR Awards
SBIR-STTR Award
10
M Tuberculosis Strain Genotyping By Mass Spectrometry
Award last edited on: 3/5/02
Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$100,000
Award Phase
1
Solicitation Topic Code
-----
Principal Investigator
Daniel P Little
Company Information
Sequenom Inc
3595 John Hopkins Court
San Diego, CA 92121
(858) 202-9000
N/A
www.sequenom.com
Location:
Multiple
Congr. District:
50
County:
San Diego
Phase I
Contract Number:
1R43AI047528-01
Start Date:
00/00/00
Completed:
00/00/00
Phase I year
2000
Phase I Amount
$100,000
Mycobacterium tuberculosis remains the most successful human pathogen on the globe. One third of the world population is infected with TB, which is responsible for 3 million deaths annually. The rise of multi-drug resistant TB and the co-infection with HIV both add to the global concerns of effectively controlling TB in the coming millennium. The slow growth of M. tuberculosis confounds diagnosis and treatment and it takes several weeks for culture confirmation and drug susceptibility testing. The goal of Phase I study is to examine the feasibility of using advances in the MALDI-mass spectrometry developed at Sequenom Inc to determine whether this platform is amenable to rapid genotyping of rifampin resistance in M. tuberculosis. Representative mutations in the well-characterized rpoB gene will be used as a test system to evaluate the feasibility of extending this platform for high throughput genotyping against all known drug resistance genes. This proposal brings together the Sequenom DNA chip technology and the PHRI TB Center's expertise in the genetic characterization of M. tuberculosis and its large strain repository. PROPOSED COMMERCIAL APPLICATION: Commercial applications for determining drug resistance in clinical isolates of M. tuberculosis
Phase II
Contract Number:
----------
Start Date:
00/00/00
Completed:
00/00/00
Phase II year
----
Phase II Amount
----
×
Login to your account
Mail sent successfully.
Enter any username and password.
Username
Password
Remember me
Login
Forgot your username?
Click here for assistance
Forgot your password?
Request new password
Don't have an account?
Sign up
Forgot username?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.
Forgot password?
Mail sent successfully.
Enter username and password.
Please enter email address that is associated with your account.
Back
Submit
Still Need Help?
If you need further assistance, send us an
e-mail
and we will assist you in resetting your account.